REG - Synairgen plc - Result of AGM

SynairgenAnnouncement

29/06/2023 18:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230629:nRSc4547Ea&default-theme=true

RNS Number : 4547E  Synairgen plc  29 June 2023

 

Synairgen plc

('Synairgen' or the 'Company')

Results of Annual General Meeting

 

Southampton, UK - 29 June 2023: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, announces the
results of voting at its Annual General Meeting today. All resolutions
proposed at its Annual General Meeting were passed.

The full results of the proxy voting and text of the resolutions can be viewed
by visiting the Company's website at www.Synairgen.com
(http://www.Synairgen.com) .

 

 

For further enquiries, please contact:

 

finnCap (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

cscsynairgen@consilium-comms.com (mailto:cscsynairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

 

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com (mailto:MConway@MKCStrategies.com)

Tel: +1 516-606-6545

 

 

 

 

Notes for Editors

 

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery,
development and commercialisation. The Company's primary focus is developing
SNG001 (inhaled interferon beta) for the treatment of severe viral lung
infections as potentially the first host-targeted, broad-spectrum antiviral
treatment delivered directly into the lungs. SNG001 has been granted Fast
Track status from the US Food and Drug Administration (FDA). Founded by
University of Southampton Professors Sir Stephen Holgate, Donna Davies and
Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more
information about Synairgen, please see www.synairgen.com
(http://www.synairgen.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBRGDLBGDDGXC